Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.

@article{Krger2001HydroxamatetypeMM,
  title={Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.},
  author={Achim Kr{\"u}ger and Rita Soeltl and Igor Sopov and Charlotte C Kopitz and Marcus Arlt and Viktor Magdolen and Nadia Harbeck and Bernd G{\"a}nsbacher and Manfred Schmitt},
  journal={Cancer research},
  year={2001},
  volume={61 4},
  pages={1272-5}
}
Overexpression of matrix metalloproteinases (MMPs) facilitates tumor cell invasion. Synthetic MMP inhibitors such as batimastat have been designed to treat cancer. We report that because of batimastat treatment, human breast carcinoma cells metastasized to the liver in nude mice and that an increase of liver metastases of murine T-cell lymphoma cells was observed in syngeneic mice. Batimastat treatment also caused liver-specific overexpression of MMPs-2, -9, and mRNA up-regulation of… CONTINUE READING
62 Citations
24 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 62 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

European roundup: no anticancer benefit in trials of marimastat

  • S. Fox
  • Genet. Eng. News,
  • 2000

Similar Papers

Loading similar papers…